Recent studies have identified multiple EGFR- and KRAS-independent mechanisms for lung cancer progression including upregulation of mesenchymal-epithelial transition factor (MET)16, and progressive disease eventually develops in GBM patients regardless of MGMT promoter methylation status17. This evidence concerns the gene EGFR and lung cancer.